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Adult T cell leukemia (ATL) is an aggressive malignancy that is associated with HTLV-I infection and characterized
by constitutive expression of the high-affinity interleukin-2 receptor. The a subunit of the high-affinity receptor (IL-2Ra),
which is normally present only on activated T cells, is specifically upregulated by HTLV-I and constitutively expressed
on fresh leukemic cells from ATL patients as well as cell lines transformed by HTLV-I in vitro. Here we directly address
the functional significance of IL-2Ra expression in HTLV-I transformed cell lines by using an endoplasmic reticulum-
targeted single-chain antibody to inhibit the cell surface expression of IL-2Ra. Using constitutive and tetracycline-
repressible systems to express the ER-targeted antibody against IL-2Ra, we have reduced cell surface expression of
IL-2Ra by more that 2 logs of mean fluorescence intensity to virtually undetectable levels in the IL-2-independent HTLV-
I-transformed cell lines C8166-45 and HUT102. No toxicity was associated with the intracellular retention of IL-2Ra,
and the growth rate of the IL-2Ra-negative cells was in each case comparable to that of the parental cell line. We
conclude that cell surface expression of IL-2Ra is dispensable for the in vitro growth of these HTLV-I-transformed cells.
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INTRODUCTION constitutive upregulation of IL-2Ra, the a subunit of the
high-affinity interleukin-2 receptor (Hattori et al., 1981;
Adult T cell leukemia (ATL) is an aggressive and rap-
Popovic et al., 1983; Waldmann et al., 1984). The high
idly fatal T cell malignancy associated with HTLV-I infec-
affinity IL-2 receptor (Kd 10
011 M) is a trimer composed
tion (Uchiyama et al., 1977). About 1% of virus carriers of a, b, and g chains (Minami et al., 1993). The b and g
develop the disease and there is currently no effective chains (IL-2Rb and gc), which are critical for IL-2 signaltreatment. The molecular basis of T cell transformation transduction, are present on both resting and activated
by HTLV-I is poorly understood but does not appear to T cells and together form a functional receptor with lower
involve any of the classical oncogenic mechanisms (on- affinity for IL-2 (Kd10
09 M). In contrast, the IL-2Ra chain—
cogene transduction, insertional mutation, or cis-activa- and hence the high-affinity receptor—is expressed only
tion of cellular oncogenes) that are employed by murine transiently following antigenic stimulation of the cell
and avian retroviruses (Cann et al., 1990). The Tax protein (Smith and Cantrell, 1985). The constitutive expression
of HTLV-I is thought to play a role in the early stages of of IL-2Ra by HTLV-I-transformed cells has led to the hy-
leukemogenesis, as it activates a variety of genes in- pothesis that constitutive signaling by the IL-2 receptor
volved in cellular growth (Gitlin and Shimotohno, 1993; may be a key factor in the growth of HTLV-I-transformed
Franchini, 1995) and is the only viral gene required to cells. A simple autocrine IL-2 mechanism can be ruled
immortalize primary T cells in vitro (Akagi et al., 1993; out in most cases, as a majority of fresh ATL cells and
Grassman et al., 1992). However, the expression of tax many HTLV-I-immortalized cell lines neither produce nor
and other viral genes is generally undetectable in freshly respond to IL-2 (Tendler et al., 1990; Arya et al., 1984;
isolated leukemic (ATL) cells, suggesting that growth of Kodaka et al., 1989; Uchiyama et al., 1985; Maeda et al.,
the end-stage leukemic cell is driven by an alternative, 1985). An alternative hypothesis of ligand (IL-2)-indepen-
tax-independent, mechanism (Franchini et al., 1984; Ten- dent signaling by an aberrant or constitutively activated
dler et al., 1990). IL-2 receptor has therefore been proposed (Yodoi et al.,
One of the phenotypic hallmarks of leukemic (ATL) 1983). While formally untested, indirect support for this
cells and T cells immortalized by HTLV-I in vitro is the model has come from reports documenting the constitu-
tive phosphorylation of IL-2Rb in HUT102 cells, and con-
stitutive activation of the IL-2Rg-associated tyrosine ki-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (617) 632-3889. E-mail: wayne_marasco@dfci.harvard.edu. nase Jak3 in several IL-2-independent HTLV-I-trans-
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formed cell lines (Sharon et al., 1989; Migone et al., 1995; LNCX as an XhoI–BamHI fragment, replacing the CMV
promoter. To construct the 10-3Tac vector, the sFvTacXu et al., 1995).
A direct way to investigate the significance of IL-2Ra gene was cloned into the pUHD10-3 (Grossen and Bu-
jard, 1992) vector as a HindIII– XbaI fragment. A hygro-upregulation in HTLV-I-transformed cells would be to ex-
amine the fate of cells in which the expression of this mycin selectable marker from the vector p3*SS (Stra-
tagene, La Jolla, CA) was inserted into the vector at areceptor subunit has been abolished. This could be
achieved by homozygous mutation of the IL-2Ra genes second HindIII site. sFvTac is a single-chain antibody
derivative of the anti-Tac monoclonal antibody whichor by using antisense RNA to prevent translation of the
IL-2Ra mRNA. An alternative strategy employed here in- binds to the extracellular domain of IL-2Ra (Uchiyama et
al., 1981). The version of sFvTac used here has a C-volves the use of intracellular antibodies (termed ‘‘intra-
bodies’’) which are synthesized by the cell and targeted to terminal ER retention signal (amino acids K-D-E-L) and
was designated sFvTacKDEL in a previous publicationthe endoplasmic reticulum (ER). ER-targeted intrabodies
have proved to be highly effective at capturing specific (Richardson et al., 1995).
proteins as they enter the ER and preventing their trans-
port to the cell surface (Richardson and Marasco, 1995). Construction of stably transfected cell lines
When combined with an inducible expression system,
ER-targeted intrabodies represent a powerful and revers- Generation of producer cell lines. The retroviral vector
LNITA was introduced into the ecotropic packaging cellible way to downregulate plasma membrane or secreted
proteins. We have previously described a single-chain line PE501 by calcium phosphate transfection. Forty-
eight hours later, supernatant from these cells was usedantibody (sFvTac) directed against the external domain
of IL-2Ra and shown that intracellular expression of this to infect PA317 cells in the presence of 8 mg/ml poly-
brene. G418 selection was applied at 600 mg/ml to theintrabody leads to complete inhibition of cell surface IL-
2Ra expression in stimulated Jurkat cells (Richardson et PA317 cells 24 hr postinfection for the selection of stable
cell lines.al., 1995). Here we have used the sFvTac intrabody to
study the consequences of IL-2Ra downregulation in Generation of tTA-expressing T cell lines. A 0.45-mm
filtered supernatant from bulk or cloned LNITA producerHTLV-I-transformed cells.
lines was used to infect 1 1 106 target cells. G418 selec-
tion was applied 24 hr later at 800 mg/ml. Two weeksMETHODS
later, single-cell clones were obtained by seeding the
Cell culture G418-resistant cells at 0.3 cell per well of a 96-well plate
in the presence of 25% conditioned medium. G418 selec-The cell lines PE501 and PA317 were grown in Dulbec-
tion and subsequent cloning were performed in the ab-co’s modified Eagles medium supplemented with 10%
sence of tetracycline to ensure the tTA-tolerance of se-fetal bovine serum and antibiotics and maintained under
lected cells. Individual clones were screened for tTA ac-HAT selection. The T cell lines Jurkat, Kit225, C8166-45,
tivity by transient transfection with a phCMV*-1CATand HUT102 (Hori et al., 1987; Salahuddin et al., 1983;
reporter plasmid. Transfected cells were cultured for 72Miyoshi et al., 1981) were grown in RPMI-1640 with 10%
hr in the presence or absence of tetracycline and thenfetal bovine serum and antibiotics. Kit225 medium was
harvested and analyzed for CAT activity. Clones demon-supplemented with 100 units/ml recombinant human in-
strating a low baseline transcription from the phCMV*-1terleukin-7. Tetracycline hydrochloride was added at 1
promoter and high inducibility on withdrawal of tetracy-mg/ml for suppression of tTA activity.
cline were used for further studies.
Introduction of 10-3Tac into stable tTA cell lines. ThePlasmid constructions
10-3Tac vector was linearized at an XmnI site within the
b-lactamase gene and introduced into T cell lines byTo construct LNITA, the tTA gene was PCR amplified
from pUHD15-1 (Grossen and Bujard, 1992) and cloned electroporation. Hygromycin selection was applied after
48 hr at 250 to 400 mg/ml and resistant cells were cloneddownstream of the encephalomyocarditis virus (EMCV)
internal ribosome entry site (IRES) in pCITE, purchased as described above. Both selection and cloning were
performed in the presence of tetracycline.from Novagen (Madison, WI). The nucleotides sur-
rounding the tTA initiation codon (underlined) were modi- Introduction of the sFvTac gene using a bicistronic
HIV-1 based retroviral vector. Constitutive, high level ex-fied to create an NcoI site (ATATGTCT r CCATGGCT),
which allowed precise positioning of the tTA initiation pression of the sFvTac gene was achieved by stably
transducing cell lines with an HIV-1 vector, in which thecodon at the natural EMCV polyprotein start site. The
changes result in a serine to alanine substitution at posi- selectable marker and gene of interest are translated
from the same mRNA by means of an internal ribosometion two. The IRES and tTA gene were PCR-amplified
from pCITE and inserted into the murine retroviral vector entry site (submitted). Vector particles were produced in
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stably introduced into several T cell lines using the mu-
rine retroviral vector LNITA (Fig 1). The tTA protein con-
sists of the DNA-binding domain of the Escherichia coli
tet repressor fused to the activation domain of the herpes
simplex virus transactivator VP16 and activates transcrip-
tion from a minimal promoter (designated phCMV*-1),
which contains multiple binding sites for the tet repressor
(Grossen and Bujard, 1992). The tTA protein is unable to
interact with the promoter in the presence of tetracycline;
hence, transcriptional activation can only occur in the
absence of tetracycline. tTA-expressing clones dis-
FIG. 1. LNITA and 10-3Tac vectors used to achieve tetracycline- playing a normal morphology and growth rate were iden-repressible expression of the sFvTac gene.
tified as described under Materials and Methods.
COS-1 cells as described elsewhere (Richardson and Tetracycline-repressible knockout of IL-2Ra in the T
Lever, 1995) and vector-containing cells were selected cell line Kit225
in the presence of puromycin (0.5 mg/ml).
The ability of the tetracycline-repressible system to
Flow cytometry downregulate a highly abundant receptor was first estab-
lished using the cell line Kit 225 (Hori et al., 1987). Kit225Cells were stained indirectly with anti-Tac or 7G7/B6
is a cytokine-dependent, HTLV-I-negative cell line de-monoclonal antibodies followed by FITC-conjugated goat
rived from a chronic T cell leukemia, which expressesanti-mouse IgG and analyzed by flow cytometry.
high levels of IL-2Ra and can be maintained using either
Metabolic labeling of cells and immunoprecipitation IL-2 or IL-7. Kit225 cells doubly transfected with the
LNITA and 10-3Tac vectors showed a reduction in cellFor metabolic labeling, 31 106 cells were washed with
surface expression of IL-2Ra by more than 2 logs ofPBS and incubated for 6 hr with or without tetracycline in
mean fluorescence intensity when tetracycline was re-3 ml cysteine-free RPMI 1640 containing 10% FBS and
moved (Fig 2). Immunoprecipitation studies showed full100 mCi [35S]cysteine. Cells were lysed in RIPA buffer
induction of sFvTac expression within 24 hr of tetracy-and cleared lysates incubated with mAb 7G7/B6 coupled
cline withdrawal. No new IL-2Ra was expressed at theto protein A–Sepharose beads for immunoprecipitation
cell surface from this time, as judged by the absence ofof IL-2Ra. Precipitation of sFvTac was then performed
the mature p55 in cell lysates (Fig 2a). Instead, the cellsusing polyclonal rabbit anti-mouse IgG from Sigma (St.
accumulated a 40-kDa molecule (p40) which we haveLouis, MO) bound to protein A–Sepharose beads. Sam-
previously shown to be an endoglycosidase-H sensitiveples were washed five times with lysis buffer then run
precursor of IL-2Ra trapped in a pre-Golgi compartmenton a 10% SDS–PAGE gel which was fixed and treated
(Richardson et al., 1995). As the 7G7/B6 mAb used forwith Enhance from DuPont-NEN (Boston, MA) prior to
immunoprecipitation of IL-2Ra does not recognize theautoradiography.
same epitope as anti-Tac, the sFvTac intrabody can be
Tritiated-thymidine incorporation assay seen coprecipitating with p40 (lanes 8–12).
Despite the rapid shut off in IL-2Ra maturation andKit225 cells were washed three times with PBS then
transport, significant levels of IL-2Ra persisted at the cellincubated in cytokine-free medium for 96 hr in the pres-
surface for up to 72 hr following tetracycline withdrawalence or absence of tetracycline. The cytokine-starved
(Fig 2b). This probably reflects the long half-life of IL-cells were then washed again and plated in triplicate
2Ra molecules already present at the time of sFvTac(with or without tetracycline) at 1 1 104 cells per well of
induction, as previous studies have shown IL-2Ra to bea 96-well plate. IL-2 or IL-7 were added at doses ranging
recycled to the cell surface following endocytosis, re-from 0.1 to 1000 units/ml and 48 hr later, wells were
sulting in a half-life of greater than 24 hr (Hemar et al.,pulsed with 1 mCi [3H]thymidine. Cells were harvested
1995). The cell surface expression of IL-2Rb and gc on18 hr later and [3H]thymidine incorporation was mea-
the IL-2Ra-negative cells was confirmed by FACS analy-sured by liquid scintillation counting.
sis (data not shown).
RESULTS
Downregulation of IL-2Ra is accompanied by loss ofConstruction of cell lines expressing a tetracycline-
IL-2 responsivenessrepressible transcriptional activator (tTA)
As a first step toward achieving inducible expression As IL-2Rb and gc expression is preserved on the IL-
2Ra-negative Kit225 cells maintained in the absence ofof the sFvTac gene, the hybrid transactivator, tTA, was
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FIG. 2. Tetracycline-repressible expression of sFvTac in Kit225 cells. (a) Immunoprecipitation of IL-2Ra and sFvTac from cells grown in the
presence (lanes 1, 7) or absence (lanes 2–6, 8–12) of tetracycline for 1–5 days. IL-2Ra was precipitated with mAb 7G7/B6 and sFvTac with rabbit
anti-mouse IgG. (b) Flow cytometric analysis of Kit225 cells stained with anti-Tac (right curve) or with secondary antibody alone (left curve). Cells
were analyzed 1–4 days after tetracycline withdrawal, as indicated. Top panel shows cells maintained in the presence tetracycline.
tetracycline, these cells would be expected to express sFvTac in 90% of transduced cells (submitted). The
intermediate-affinity (b/g) IL-2 receptors but not the high- HTLV-I-negative Jurkat cell line, in which IL-2Ra expres-
affinity (abg) receptor. A [3H]thymidine incorporation sion can be induced by stimulation with PHA and PMA,
assay was used to evaluate the IL-2-responsiveness of was also transduced with the HVTac vector. Flow cyto-
Kit225 cells grown in the presence or absence of tetracy- metric analysis of the transduced cells after staining with
cline. As shown in Fig. 3, between 102- and 103-fold anti-Tac monoclonal antibody indicated that IL-2Ra sur-
higher concentrations of IL-2 were required to generate face expression intensity could be reduced by more than
an equivalent proliferative response in IL-2Ra-negative 2 logs of mean fluorescence intensity to a level undetect-
cells, whereas the response of these cells to IL-7 was able by flow cytometric analysis in both C8166-45 and
not affected. This is consistent with the higher IL-2 con- HUT102 cells as well as the control Jurkat cells (Fig. 4).
centration required to signal through the b/g receptor Use of the tetracycline-repressible system in fact proved
and indicates that the ER-retention of IL-2Ra molecules unnecessary as both HTLV-I-infected cell lines were
does not interfere with the cell surface transport or func- found to tolerate long-term, constitutive downregulation
tion of IL-2Rb and gc . The IL-2 responsiveness of Kit225 of IL-2Ra without any adverse effect on cell growth. The
cells transfected with the LNITA vector alone was unaf- doubling times of both parent and IL-2Ra-negative
fected by the presence or absence of tetracycline, con- C8166-45 cells was 26 hr, and parent and IL-2Ra-nega-
firming that expression of the tTA gene does not affect tive HUT102 cells doubled every 18–20 hr (Fig. 5). To
IL-2R signaling (data not shown). eliminate the possibility that IL-2Ra was present at the
cell surface but masked by sFvTac (which might be co-
Downregulation of IL-2Ra in HTLV-I transformed cell transported to the cell surface or released by dead cells),
lines the cells were stained with the monoclonal antibody 7G7/
B6, which recognizes a different and noncompeting IL-To examine the consequences of IL-2Ra downregula-
2Ra epitope (Rubin et al., 1985). The lack of staining withtion in HTLV-I-transformed cells, the sFvTac gene was
7G7/B6 confirmed that IL-2Ra was indeed not present atstably introduced into the cell lines C8166-45 and
the cell surface (Fig. 4 and data not shown). Immunopre-HUT102 under the control of tetracycline repressible or
cipitation studies further confirmed the absence of ma-constitutive promoters. For constitutive expression, a
ture p55 and the accumulation of p40 in the sFvTac-HIV-1-based retroviral vector (HVTac) was used which
we have shown to provide high level expression of expressing cells (Fig. 6, lane 2). As the growth rate of
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FIG. 5. Growth rate studies for parental and sFvTac-expressing
C8166-45 cells (left panel) and HUT102 cells (right panel). Open
symbol, parental cell line; closed symbol, sFvTac-expressing line.
Arrows indicate days on which cells were split and seeded at 1 or
4 1 104 cells/ml.
FIG. 3. IL-2-induced proliferation of 10-3Tac-transfected Kit225 cells DISCUSSION
maintained in the presence or absence of tetracycline.
Single-chain antibodies synthesized by the cell and
targeted to the relevant cellular compartment have been
used to interfere in a highly specific manner with diversethe IL-2Ra-negative cells was in each case comparable
with that of the parental cell line, we conclude that cell biological processes ranging from growth factor signal-
ing to the replication and assembly of the human immu-surface expression of IL-2Ra is dispensable for the in
vitro growth of these HTLV-I-transformed cells. These nodeficiency virus (HIV-1) (Richardson and Marasco,
1995). Our demonstration here that IL-2Ra surface ex-studies do not rule out the possibility that immature IL-
2Ra (p40) molecules retained in the ER may somehow pression can be reduced to a level undetectable by flow
cytometric analysis in three T cell leukemia lines whichfunction to promote cell growth. This seems unlikely,
however, in view of the fact that this receptor subunit is normally express 200,000 molecules per cell indicates
the extraordinary power of this technology to downregu-required for efficient ligand (IL-2) binding but does not
appear to play a role in downstream signaling events late even highly abundant cell surface receptors. When
coupled with an inducible or repressible expression sys-(Minami et al., 1993).
FIG. 4. Flow cytometric analysis of Jurkat, C8166-45, and HUT102 cells stably transduced with the HIV-1-based retrovirus vector, HVTac. Parental
or transduced cells were stained with anti-Tac, 7G7/B6, or a control antibody, as indicated.
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pendence to independence has been observed in many
cell lines immortalized by HTLV-1 in vitro (Popovic et al.,
1983; Hoshino et al., 1983; Yssel et al., 1989; Inatsuki et
al., 1989).
While data presented here suggests that expression
of the IL-2Ra subunit is not required for the growth of
HTLV-I-immortalized cells, the role of bg receptor signal-
ing in the growth of both these and fresh ATL cells is an
important area that requires further investigation. Two
recent reports suggest that the switch to IL-2 indepen-
dence in HTLV-I-immortalized lines may be associated
with the constitutive activation of Jak3, a tyrosine kinase
FIG. 6. Immunoprecipitation of IL-2Ra and sFvTac from C8166-45 associated with the IL-2 receptor (Migone et al., 1995;
cells (lanes 1 and 3) or C8166-45 cells stably transduced with HVTac Xu et al., 1995). Normally activated upon IL-2 binding, it
(lanes 2 and 4). IL-2Ra was precipitated with mAb 7G7/B6 and sFvTac
appears that the Jak3 can be activated by alternativewith rabbit anti-mouse IgG.
mechanisms in certain cells, resulting in the constitutive
activation of Stat factors. In murine pre-B lymphocytes
transformed by the v-abl oncogene, the abl kinase itselftem, intracellular antibodies represent a highly versatile
tool for the manipulation of cellular signaling pathways. may be responsible for Jak3 phosphorylation (Danial et
al., 1995). The mechanism of Jak3 activation in HTLV-I-The finding that IL-2Ra is not required for the in vitro
growth of HTLV-I-transformed cell lines poses two im- transformed cells has yet to be determined but may per-
haps involve the action of p12I, an HTLV-I gene productportant questions. First, what is the purpose of IL-2Ra
upregulation on these cells and second, what signals of unknown function which is reported to interact with
both IL-2Rb and gc (Mulloy et al., 1996). The constitutiveare driving the proliferation of leukemic cells in ATL? The
functional significance of IL-2Ra upregulation has been activation of Jak-Stat signaling pathways has recently
been demonstrated in other human leukemias and aninferred from the fact that multiple mechanisms exist to
maintain high level IL-2Ra expression in HTLV-I-trans- inhibitor of Jak2 was found to inhibit the in vitro prolifera-
tion of acute lymphoblastic leukemia cells (Meydan etformed cells. In cells productively infected by HTLV-I, the
viral proteins Tax and Rex induce the expression of IL- al., 1996; Gouilleux-Gruart et al., 1996). In light of the
apparent link between Jak-Stat activation and cell prolif-2Ra by enhancing both the synthesis and stability of IL-
2Ra mRNA (Siekevitz et al., 1987; Kanamori et al., 1990). eration in other leukemias, the bg receptor and associ-
ated signaling pathways may represent a strategic thera-In leukemic cells, where the HTLV-I provirus is transcrip-
tionally silent, the mechanism of IL-2Ra upregulation is peutic target in adult T cell leukemia. The development
of intracellular antibodies directed against IL-2Rb andless well understood but may be related to the production
of ATL-derived factor (ADF), the human homolog of thio- gc should permit direct experimental testing of this hy-
pothesis.redoxin. Originally identified as an IL-2Ra-inducing factor
released by ATL cells, ADF is a redox-regulator which
appears to indirectly stimulate the IL-2Ra promoter ACKNOWLEDGMENTS
(Teshigawara et al., 1985; Yodoi and Uchiyama, 1992).
This work was supported by the Leukemia Research Foundation,The finding that IL-2Ra is dispensable for the growth
the National Foundation for Cancer Research, the Mathers Foundation
of HTLV-I-transformed lines in vitro suggests that IL-2Ra and Friends 10. We thank Dr. Bujard for plasmids pUHD15-5 and
is not serving a function related to cell growth. It is possi- pUHD10-3, Dr. A. Grant for the Kit225-B6/7 subclone, and Dr. D. Miller
for cell lines PE501 and PA317.ble that IL-2Ra expression is an irrelevant consequence
of Tax or ADF activity in immortalized lines and ATL cells,
respectively, but perhaps a more likely explanation is REFERENCES
that the high-affinity IL-2R was required for IL-2-mediated
Akagi, T., and Shimotohno, K. (1993). Proliferative response of Tax1-growth at an earlier stage in the leukemogenic or immor-
transduced primary human T cells to anti-CD3 antibody stimulation
talization process. Several observations suggest that by an interleukin-2-independent pathway. J. Virol. 67, 1211–1217.
loss of IL-2 dependence may be a relatively late event Akagi, T., Ohno, H., and Shimotohno, K. (1996). Expression of cell-cycle
regulatory genes in HTLV-I infected T-cell lines: Possible involvementin leukemogenesis, that is separable from the process
of Tax1 in the altered expression of cyclin D2, p18Ink4 and p21Waf1/of immortalization. First, in a small number of ATL pa-
Cip1/Sdi1. Oncogene 12, 1645–1652.tients with chronic or acute disease, the leukemic cells
Arima, N., Daitoku, Y., Ohgaki, S., Fukumori, J., Tanaka, H., Yamamoto,
retain the capacity to respond to IL-2 and may be repre- Y., Fujimoto, K., Onoue, K. (1986). Autocrine growth of interleukin 2-
sentative of an earlier-stage cell (Maeda et al., 1985, producing leukemic cells in a patient with adult T cell leukemia.
Blood 68, 779–782.1987; Arima, 1986). Second, a progression from IL-2 de-
AID VY 8779 / 6a4f$$$162 10-01-97 12:49:52 viras AP: VY
215IL-2Ra KNOCKOUT IN HTLV-I-TRANSFORMED CELLS
Arya, S. K., Wong-Staal, F., and Gallo, R. C. (1984). T-cell growth factor Meydan, N., Grunberg, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z.,
Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., andgene: Lack of expression in human T-cell leukemia-lymphoma virus-
infected cells. Science 223, 1086–1087. Roifman, C. M. (1996). Inhibition of acute lymphoblastic leukaemia
by a Jak-2 inhibitor. Nature 379, 645–648.Cann, A. J., and Chen, I. S. Y. (1990). Human T-cell leukemia virus types
I and II. In ‘‘Virology’’ (B. N. Fields and D. M. Knipe, Eds.), p. 1501. Migone, T. S., Lin, J. X., Cereseto, A., Mulloy, J. C., O’Shea, J. J., Franchini,
G., and Leonard, W. J. (1995). Constitutively activated Jak-STAT path-Raven Press, New York.
Danial, N. N., Pernis, A., and Rothman, P. B. (1995). Jak-STAT signaling way in T cells transformed with HTLV-I. Science 269, 79–81.
Minami, Y., Kono, T., Miyazaki, T., and Taniguchi, T. (1993). The IL-2induced by the v-abl oncogene. Science 269, 1875–1877.
Franchini, G. (1995). Molecular mechanisms of Human T-cell Leukemia/ receptor complex: its structure, function and target genes. Annu. Rev.
Immunol. 11, 245–267.Lymphotropic Virus Type 1 infection. Blood 86, 3619–3639.
Franchini, G., Wong-Staal, F., and Gallo, R. C. (1984). Human T-cell Miyoshi, I., Kubonishi, I., Yoshimoto, S., Akagi, T., Ohtsuki, Y., Shiraishi,
Y., Nagata, K., and Hinuma, Y. (1981). Type C-virus particles in a cordleukemia virus (HTLV-I) transcripts in fresh and cultured cells of
patients with adult T-cell leukemia. Proc. Natl. Acad. Sci. USA 81, T-cell line derived by co-cultivating normal human cord leukocytes
and human leukaemic T cells. Nature 294, 770–771.6207–6211.
Gitlin, S. D., Dittmer, J., Reid, R. L., and Brady, J. N. (1993). The molecular Mulloy, J. C., Crowley, R. W., Fullen, J., Leonard, W. J., and Franchini, G.
(1996). The human T-cell leukemia/lymphotropic virus type 1 p12Ibiology of human T-cell leukemia viruses. In ‘‘Frontiers in Molecular
Biology’’ (B. Cullen, Ed.), pp. 159–192. Oxford Univ. Press, Oxford, protein binds the interleukin-2 receptor b and gc chains and affects
their expression on the cell surface. J. Virol. 70, 3599–3605.UK.
Gouilleux-Gruart, V., Gouilleux, F., Desaint, C., Claisse, J-F., Capiod, Popovic, M., Lange-Wantzin, G., Sarin, P. S., Mann, D., and Gallo, R. C.
(1983). Transformation of human umbilical cord blood T cells byJ-C., Delobel, J., Weber-Nordt, R., Dusanter-Fourt, I., Dreyfus, F.,
Groner, B., and Prin, L. (1996). STAT-related transcription factors are human T-cell leukemia/lymphoma virus. Proc. Natl. Acad. Sci. USA
80, 5402–5406.constitutively activated in peripheral blood cells from acute leukemia
patients. Blood 87, 1692–1697. Richardson, J. H., and Marasco, W. A. (1995). Intracellular antibodies:
Development and therapeutic potential. Trends Biotechnol. 13, 306–Grassman, R., Berchtold, S., Radant, I., Alt, M., Fleckenstein, M., So-
droski, J. G., Haseltine, W. A., and Ramstedt, U. (1992). Role of human 310.
Richardson, J. H., Sodroski, J. G., Waldmann, T. A., and Marasco, W. A.T-cell leukemia virus type 1 X region proteins in immortalization of
primary human lymphocytes in culture. J. Virol. 66, 4570–4575. (1995). Phenotypic knockout of the high-affinity human interleukin 2
receptor by intracellular single-chain antibodies against the a subunitGrossen, M., and Bujard, H. (1992). Tight control of gene expression
in mammalian cells by tetracycline-responsive promoters. Proc. Natl. of the receptor. Proc. Natl. Acad. Sci. USA 92, 3137–3141.
Richardson, J. H., and Lever, A. M. L. (1995). HIV-1 Vectors. In ‘‘HIVAcad. Sci. USA 89, 5547–5551.
Hattori, T., Uchiyama, T., Toibana, T., Takatsuki, T., and Uchino, H. Techniques: A Practical Approach’’ (J. Karn, Ed.), pp. 89–113. IRL
Press, Oxford.(1981). Surface phenotype of Japanese adult T-cell leukemia cells
characterized by monoclonal antibodies. Blood 58, 645–647. Rubin, L. A., Kurman, C. C., Biddison, W. E., Goldman, N. D., and Nelson,
D. L. (1985). A monoclonal antibody 7G7/B6, binds to an epitopeHemar, A., Subtil, A., Lieb, M., Morelon, E., and Hellio, R. (1995). Endocy-
tosis of interleukin 2 receptors in human T lymphocytes: Distinct on the human interleukin-2 (IL-2) receptor that is distinct from that
recognized by IL-2 or anti-Tac. Hybridoma 4, 91–102.intracellular localization and fate of the receptor a, b and g chains.
J. Cell Biol. 129, 55–64. Salahuddin, S. Z., Markham, P. D., Wong-Staal, F., Franchini, G., Kalya-
naraman, V. S., and Gallo, R. C. (1983). Restricted expression of hu-Hori, T., Uchiyama, T., Tsudo, M., Umadome, H., Ohno, H., Fukuhara,
S., Kita, K., and Uchino, H. (1987). Establishment of an interleukin man T-cell leukemia-lymphoma virus (HTLV) in transformed human
umbilical cord blood lines. Virology 129, 51–64.2-dependent human T cell line from a patient with T cell chronic
lymphocytic leukemia who is not infected with human T cell leuke- Sharon, M., Gnarra, J. R., and Leonard, W. J. (1989). The beta-chain of
the IL-2 receptor (p70) is tyrosine-phosphorylated on YT and HUT-mia/lymphoma virus. Blood 70, 1069–1072.
Hoshino, H., Esumi, H., Miwa, M., Shimoyama, M., Minato, K., Tobinai, 102B2 cells. J. Immunol. 143, 2530–2533.
Siekevitz, M., Feinberg, M. B., Holbrook, N., Wong-Staal, F., and Greene,K., Hirose, M., Watanabe, S., Inada, N., Kinoshita, K., Kamihira, S.,
Ichimaru, M., and Sugimura, T. (1983). Establishment and character- W. C. (1987). Activation of interleukin 2 and interleukin 2 receptor
(Tac) promoter expression by the trans-activator (tat) gene productization of 10 cell lines derived from patients with adult T-cell leuke-
mia. Proc. Natl. Acad. Sci. USA 80, 6061–6065. of human T cell leukemia virus, type I. Proc. Natl. Acad. Sci. USA 84,
5389–5393.Inatsuki, A., Yasukawa, M., and Kobayashi, Y. (1989). Functional alter-
ations of herpes simplex virus-specific CD4/ multifunctional T cell Smith, K. A., and Cantrell, S. A. (1985). Interleukin 2 regulates its own
receptors. Proc. Natl. Acad. Sci. USA 82, 864–868.clones following infection with human T cell lymphotropic virus type
I. J. Immunol. 143, 1327–1333. Tendler, C. L., Greenberg, S. J., Blattner, W. A., Manns, A., Murphy, E.,
Fleisher, T., Hanchard, B., Morgan, O., Burton, J. D., Nelson, D. L., andKanamori, H., Suzuki, N., Siomi, H., Nosaka, T., Sato, A., Sabe, H., H. M.,
and Honjo, T. (1990). HTLV-1 p27rex stabilizes human interleukin-2 Waldmann, T. A. (1990). Trans-activation of interleukin 2 and its receptor
induces immune activation in human T-cell lymphotropic virus type 1-receptor a chain mRNA. Embo J. 9, 4161–4166.
Kodaka, T., U. T., Umadome, H., and Uchino, H. (1989). Expression of associated myelopathy: Pathogenic implications and a rationale for
immunotherapy. Proc. Natl. Acad. Sci. USA 87, 5218–5222.cytokine mRNA in leukemic cells from adult T cell leukemia patients.
Jpn. J. Cancer. Res. 80, 531– 536. Teshigawara, K., Maeda, M., Nishino, K., Nikaido, T., Uchiyama, T.,
Tsudo, M., Wano, Y., and Yodoi, J. (1985). Adult T cell leukemiaMaeda, M., A. N., Daitoku, Y., Kashihara, M., Okamoto, H., Uchiyama,
T., Shirono, K., Matsuoka, M., Hattori, T., Takatsuki, K., Ikuta, K., Shim- cells produce a lymphokine that augments interleukin 2 receptor
expression. J. Mol. Cell. Immunol. 2, 17–22.izu, A., Honjo, T., and Yodoi, J. (1987). Evidence for the interleukin-2
dependent expansion of leukemic cells in adult T cell leukemia. Uchiyama, T., Broder, S. A., Waldmann, T. A. (1981). A monoclonal anti-
body reactive with activated and functionally mature human T-cells.Blood 70, 1407–1411.
Maeda, M., Shimizu, A., Ikuta, K., Okamoto, H., Kashihara, M., Uchiyama, J. Immunol. 126, 1393–1397.
Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., and Uchino, H. (1977).T., Honjo, T., and Yodoi, J. (1985). Origin of human T-lymphotropic
virus 1-positive T cell lines in adult T cell leukemia: Analysis of T Adult T cell leukemia: Clinical and hematologic features of 16 cases.
Blood 50, 481–492.cell receptor gene rearrangement. J. Exp. Med. 162, 2169–2174.
AID VY 8779 / 6a4f$$$163 10-01-97 12:49:52 viras AP: VY
216 RICHARDSON ET AL.
Uchiyama, T., Hori, T., Tsudo, M., Wano, Y., Umedomo, H., Tamori, S., in human T cell leukemia virus type 1 (HTLV-I) Tax protein or virus-
transformed cells. J. Clin. Invest. 96, 1548–1555.Yodoi, J., Maeda, M., Sawami, H., and Uchino, H. (1985). Interleukin-
2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J. Yodoi, J., and Uchiyama, T. (1992). Diseases associated with HTLV-I:
Virus, IL-2 receptor dysregulation and redox regulation. Immunol.Clin. Invest. 76, 446–453.
Waldmann, T. A., Greene, W. C., Sarin, P. S., Saxinger, C., Blayney, Today 13, 405–411.
Yodoi, J., Uchiyama, T., and Maeda, M. (1983). T cell growth factorD. W., Blattner, W. A., Goldman, C. K., Bongiovanni, K., Sharrow, S.,
Depper, J. M., Leonard, W., Uchiyama, T., and Gallo, R. C. (1984). receptor in adult T cell leukemia (correspondence). Blood 62, 509–
510.Functional and phenotypic comparison of human T cell leukemia/
lymphoma virus positive adult T cell leukemia with human T cell Yssel, H., Malefyt, R., Duc Dodon, M., Blanchard, D., Gazzolo, L., de
Vries, J., and Spits, H. (1989). Human T cell leukemia/lymphomaleukemia/lymphoma virus negative Sezary leukemia, and their dis-
tinction using anti-Tac monoclonal antibody identifying the human virus type I infection of a CD4/ proliferative/cytotoxic T cell clone
progresses in at least two distinct phases based on changes inreceptor for T cell growth factor. J. Clin. Invest. 73, 1711–1718.
Xu, X., Kang, S., Heidenreich, O., Okerholm, M., O’Shea, J. J., and Ner- function and phenotype of the infected cells. J. Immunol. 142, 2279–
2289.enberg, M. I. (1995). Constitutive activation of different Jak kinases
AID VY 8779 / 6a4f$$$163 10-01-97 12:49:52 viras AP: VY
